-
Precision Diagnosis and Control: SIFIC’s milestone conference for 20 years opens, drawing a new blueprint for infection control
On July 26, 2024, the highly anticipated 20th Shanghai International Forum for Infection Control (SIFIC), in conjunction with the 8th Oriental Forum on Complex Infectious Diseases (OFCID) and the Annual Meeting of the Global Chinese Society of Clinical Microbiology and Infectious Diseases, was grandly inaugurated at the Shanghai International Conference Center. Themed “Precision Diagnosis, Precision…
-
Emerging Perspectives: July Literature Digest (Part 2)
In today’s information overload era, how can one stay updated on the latest advancements in the field? Here, we curate the most recent literature each month, focusing on hot topics and offering a comprehensive analysis of the latest developments in hematologic diseases. Join us as we track the latest trends, gain insights into scientific research,…
-
Dr. Huilai Zhang: Current Status and Treatment Progress for Chinese Patients with Marginal Zone Lymphoma 🌟 | The 8th CSCO Hematology Academic Conference—Considerations for the Application of Chemotherapy-Free Regimens
Marginal zone lymphoma (MZL), a group of indolent mature B-cell lymphomas, presents a significant challenge in treatment selection due to its high heterogeneity. Despite improvements in survival rates for MZL patients with the advent of new drugs and advancements in clinical diagnostic and therapeutic techniques, developing a balanced management plan that addresses both efficacy and…
-
ASCOBT24 | Efficacy and Patient-Reported Outcomes of Enfortumab Vedotin Combined with Pembrolizumab in Previously Untreated Locally Advanced or Metastatic Urothelial Carcinoma
For many years, platinum-based chemotherapy has been the standard treatment for metastatic urothelial carcinoma. However, this year’s EV-302/KEYNOTE-A39 study results, published in the New England Journal of Medicine (NEJM), demonstrated that the combination of enfortumab vedotin and pembrolizumab (EV+P) significantly improves survival outcomes for patients with locally advanced or metastatic urothelial carcinoma. The 2024 ASCO…
-
ASCOBT24 | Evolving Treatment Prospects for mHSPC and Optimizing Cabazitaxel Benefit in mCRPC Patients
The ASCO Breakthrough Summit, co-hosted by the American Society of Clinical Oncology (ASCO), the Japanese Society of Clinical Oncology (JSCO), and the Japanese Society of Medical Oncology (JSMO), in collaboration with several authoritative societies in the Asia-Pacific region, including the Chinese Anti-Cancer Association (CACA) and the Chinese Society of Clinical Oncology (CSCO), was held from…
-
2024 CUDA | Dr. Qiang Wei: Precision Medicine Opens a New Chapter in Prostate Cancer Patient Benefits
In the spirit of “Healthy China, Urology First,” the 2024 Annual Meeting of the Chinese Urological Association (CUDA) was grandly held in Xi’an, Shaanxi Province, from August 8th to 11th, 2024. The event showcased the latest achievements in urological medicine from a global and multidimensional perspective. In recent years, with the deepening of molecular exploration,…
-
2024 CUDA | Dr. Shun Zhang: Standardizing the Management of Prostate Cancer Bone Metastases to Maximize Patient Benefits
Prostate cancer is one of the most common malignant tumors in the male urinary system, with over 110,000 new cases diagnosed annually in China. The bones are the primary site of metastasis for prostate cancer, leading to bone-related events (BREs) such as pathological fractures, spinal cord compression, and bone pain, which significantly impact patients’ quality…
-
AIDS Five Minutes | Dr. Wei Cao: Treatment and Management Practices in the Post-HAART Era of HIV
“The continuous advancements and remarkable success of Highly Active Antiretroviral Therapy (HAART) have made long-term survival for HIV patients a reality. However, the persistent presence of the HIV virus, chronic inflammation associated with the virus, and the lifelong impact of medication have led to chronic complications, such as metabolic diseases, becoming significant factors affecting the…
Connecting Medical Expertise through Media